Previous 10 | Next 10 |
CV Sciences, Inc. Reports Third Quarter 2022 Financial Results PR Newswire SAN DIEGO , Nov. 14, 2022 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing i...
CV Sciences ( OTCQB:CVSI ) is scheduled to announce Q3 earnings results on Monday, November 14th, before market open. The consensus EPS Estimate is -$0.02 and the consensus Revenue Estimate is $4.03M (-21.1% Y/Y). Over the last 2 years, CVSI has beaten EPS estimates 50...
CV SCIENCES, INC. TO ANNOUNCE THIRD QUARTER 2022 RESULTS ON NOVEMBER 14, 2022 PR Newswire SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent supplier and manufa...
CV Sciences, Inc. Announces Proposed Settlement of Shareholder Litigation PR Newswire SAN DIEGO , Sept. 27, 2022 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company sp...
CV Sciences ( OTCQB:CVSI ) has announced today that CV Sciences extinguished its entire outstanding convertible debt. The termination of all convertible debt and related obligations to issue stock to the lender will eliminate the dilutive impact of this debt on our stockholder...
CV Sciences, Inc. Extinguishes Convertible Debt PR Newswire SAN DIEGO , Aug. 25, 2022 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts ...
CV Sciences, Inc. (CVSI) Q2 2022 Earnings Conference Call August 15, 2022, 10:00 ET Company Participants Joseph Dowling - CEO, Secretary & Director Joerg Grasser - CFO Conference Call Participants Presentation Operator Greetings, and w...
CV Sciences ( OTCQB:CVSI ) stock fell ~7% on Aug. 15 after Q2 revenue declined -19.6% Y/Y. Q2 sales were $4.1M, compared to $5.1M in the Q2 2021. The company said the decline was mainly due to lower sales in the retail channel, primarily to FDM accounts, higher discoun...
CV Sciences, Inc. Announces Launch of PlusCBD™ Reserve Collection Softgels PR Newswire PlusCBD™'s latest product leverages CBD and THC to target anxiety and stress SAN DIEGO , Aug. 15, 2022 /PRNewswire/ -- CV Sciences, Inc. (OTCQ...
CV Sciences, Inc. (OTCQB: CVSI) sales fell in the quarter as demand for hemp-derived products continues to fade. The hemp operator announced its financial results for the quarter ending June 30, 2022. CV Sciences delivered approximately $4.1 million in total revenue during the...
News, Short Squeeze, Breakout and More Instantly...
CV Sciences, Inc. Reports First Quarter 2024 Financial Results PR Newswire SAN DIEGO , May 14, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp ex...
CV SCIENCES, INC. ACQUIRES ELEVATED SOFTGELS, A FLEXIBLE, LOW-MOQ, NUTRACEUTICAL MANUFACTURER PR Newswire SAN DIEGO , May 13, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer we...
CV Sciences, Inc. To Announce First Quarter 2024 Results On May 14, 2024 PR Newswire SAN DIEGO , May 8, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company special...